Fulcrum Therapeutics, Inc. (FULC)
3.74
-0.04
(-1.19%)
USD |
NASDAQ |
Sep 25, 10:54
Fulcrum Therapeutics Research and Development Expense (Quarterly) : 12.23M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.23M |
| March 31, 2026 | 13.75M |
| December 31, 2025 | 15.07M |
| September 30, 2025 | 14.00M |
| June 30, 2025 | 12.69M |
| March 31, 2025 | 13.05M |
| December 31, 2024 | 11.34M |
| September 30, 2024 | 14.24M |
| June 30, 2024 | 16.86M |
| March 31, 2024 | 19.29M |
| December 31, 2023 | 19.00M |
| September 30, 2023 | 17.74M |
| June 30, 2023 | 17.25M |
| March 31, 2023 | 16.15M |
| December 31, 2022 | 17.98M |
| September 30, 2022 | 14.77M |
| June 30, 2022 | 24.32M |
| Date | Value |
|---|---|
| March 31, 2022 | 17.30M |
| December 31, 2021 | 18.29M |
| September 30, 2021 | 16.48M |
| June 30, 2021 | 16.68M |
| March 31, 2021 | 15.73M |
| December 31, 2020 | 15.41M |
| September 30, 2020 | 15.14M |
| June 30, 2020 | 12.18M |
| March 31, 2020 | 13.94M |
| December 31, 2019 | 11.57M |
| September 30, 2019 | 12.98M |
| June 30, 2019 | 10.86M |
| March 31, 2019 | 9.038M |
| December 31, 2018 | 6.86M |
| September 30, 2018 | 6.963M |
| June 30, 2018 | 5.788M |
| March 31, 2018 | 5.573M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | 2.142M |
| CNBX Pharmaceuticals, Inc. | -- |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 52.30M |
| Definium Therapeutics, Inc. | 48.66M |